Medication info
Glarinduo Extended-Release Tablet 2.5/1000 mg (Linagliptin, Metformin)

Glarinduo Extended-Release Tablet 2.5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Eden Pharma Co., Ltd.
Appearance
White oval extended-release film-coated tablet imprinted with D 2.5/1000 on one side
Packaging
28 tablets (7 tablets/PTPX4)/box, 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202400626 · Approved 2024.03.22 · Insurance code 628902350

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride, as extended-release, 2000 mg. This medicine should be taken with food once daily, preferably with the evening meal. For this medicine 5/1000 mg extended-release tablets, take 1 tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Because dose adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Eden Pharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to improve blood sugar control in patients with type 2 diabetes who are using Linagliptin and Metformin together. It helps effectively manage blood sugar levels in conjunction with dietary and exercise therapy, facilitating better diabetes management for patients.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride, as extended-release, 2000 mg. This medicine should be taken with food once daily, preferably with the evening meal. For this medicine 5/1000 mg extended-release tablets, take 1 tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Because dose adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication may rarely cause a dangerous condition called lactic acidosis; therefore, it should not be used, especially in patients with impaired renal function or those with acute illnesses. Patients allergic to the active ingredients, those with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, or significant liver dysfunction should not be administered this medication. Patients with acute or chronic alcohol intoxication should also avoid this medication. Since this medication can cause hypoglycemia, blood glucose levels should be closely monitored, particularly when used in conjunction with sulfonylureas or insulin. Patients with decreased renal function must undergo regular kidney function tests before and during treatment, and if function declines severely, treatment should be stopped. Patients with unstable cardiac function or acute heart failure should also use this medication with caution. Before and after receiving iodinated contrast agents used during radiological examinations, the use of this medication should be temporarily discontinued, and kidney function should be monitored. Patients scheduled for surgery should stop taking this medication 48 hours prior to the procedure and should not resume it until kidney function has stabilized afterward. Acute pancreatitis or bullous skin disease may occur during treatment; if abdominal pain or skin abnormalities appear, patients should consult a doctor immediately. The metformin component may lower vitamin B12 levels, so regular monitoring of vitamin B12 levels is necessary during long-term use. This medication is a swallowable tablet and should be taken whole without crushing or chewing. The tablet coating may appear in stool, but this is normal. Pregnant or breastfeeding women are advised to avoid using this medication and should consult a doctor if planning for pregnancy. Elderly patients may experience reduced renal function, so treatment should begin with the minimum dose, and renal function should be periodically checked. Drug interactions may occur when used with other medications; therefore, patients should inform their doctor or pharmacist of any other medications they are taking. In case of overdose, there is a risk of lactic acidosis, and immediate hospital treatment is required, which may include hemodialysis.

Side effects

Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemic episodes, taste disturbances, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigoid, arthritis associated with severity and disability, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reactions, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorders, insomnia, depression, contusions, bone contusions, concussion, bone fracture, hand fracture, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, thyroid enlargement, anemia, nausea, gastroesophageal reflux disease, gastritis, dizziness, sensory loss, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, voice disorders, nasal bleeding, rhinorrhea, androgenetic alopecia, hyperhidrosis, dermatitis, anxiety, benign prostatic hyperplasia, confusion state, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it must be stored in a tightly sealed container when in use. Moreover, it should not be kept in excessively hot or cold places and should be stored at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's efficacy over time.

Appearance and packaging

Appearance

White oval extended-release film-coated tablet imprinted with D 2.5/1000 on one side

Package unit

28 tablets (7 tablets/PTPX4)/box, 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.